Evofem Biosciences, INC 8-K filings

Evofem Biosciences has released a corporate slide presentation providing business updates to the investment community.

Evofem Biosciences has entered into a subordinated note agreement with HUB Cyber Security, Ltd. for $706,304, bearing 12% annual interest.

Evofem Biosciences reported Q1 2026 net sales of $0.9 million, a slight increase from the prior year, while focusing on international commercialization and cost reduction initiatives.

Evofem Biosciences has entered into a fourth amendment to its 2020 Securities Purchase Agreement, extending the maturity date of its convertible promissory notes by six months.

Evofem Biosciences and Windtree Therapeutics mutually agreed to terminate their License and Supply Agreement for PHEXXI manufacturing due to Windtree's failure to establish production capabilities.

Evofem Biosciences, Inc. announced it has posted an updated corporate slide presentation to its investor website, providing a summary of its business.

Evofem Biosciences stockholders approved a reverse stock split, elected four directors, and ratified executive compensation and an equity incentive plan at their annual meeting.

Evofem Biosciences announced a 10% increase in net sales and achieved $1.0 million in operating income for the third quarter of 2025, alongside significant cost reduction initiatives.

Evofem Biosciences stockholders rejected the merger with Aditxt, leading to the termination of the agreement and a strategic pivot for Evofem.

Evofem Biosciences, Inc. has amended its Securities Purchase Agreement with Adjuvant, modifying the maturity date and prepayment terms for convertible promissory notes.

Evofem Biosciences has amended its merger agreement with Aditxt for the sixth time and issued new Series G-1 Convertible Preferred Stock by exchanging $1.573 million in senior secured convertible notes.

Evofem Biosciences announced increased net sales and improved operational loss in Q2 2025, while advancing its merger plans with Aditxt.

Evofem Biosciences, Inc. has completed a private placement of senior subordinated convertible notes and warrants to Aditxt, Inc., raising approximately $925,000 in net proceeds, subject to terms that include significant investor protections and potential future dilution.

Evofem Biosciences grants Pharma 1 Drug Store exclusive rights to market and distribute SOLOSEC in the Middle East, targeting regulatory submission in the UAE by mid-2025.

Evofem Biosciences announced its Q1 2025 financial results, highlighting soft net sales due to order timing but expressing optimism for future growth and cost reduction initiatives.

Evofem Biosciences amends its agreement with Pharma 1 Drug Store L.L.C. to include a 3-applicator package size of its licensed product in addition to the existing 12-applicator package.

Aditxt secures a call option to purchase Evofem's securities from Adjuvant Global Health Technology Fund for $13 million, contingent on certain conditions and ongoing merger talks.

Evofem Biosciences and Windtree Therapeutics have amended their License and Supply Agreement to clarify terms related to manufacturing and supply of PHEXXI.

Evofem Biosciences anticipates a 55%-60% decrease in PHEXXI manufacturing costs through a new agreement with Windtree Therapeutics.

Evofem Biosciences announces a 6% increase in 2024 net sales to $19.4 million, driven by PHEXXI and the acquisition of SOLOSEC, alongside a 27% reduction in total operating expenses.

Evofem Biosciences received a notice from OTC Markets Group on January 6, 2025, indicating non-compliance with the minimum bid price requirement for continued listing on the OTCQB Venture Market.

Evofem Biosciences has announced the cancellation of its special meeting and the withdrawal of proposals previously submitted to stockholders.

Evofem Biosciences and Aditxt have amended their merger agreement for the fourth time, extending the deadline for the merger's consummation to January 31, 2025.

Evofem Biosciences announced a 31% improvement in operating loss for Q3 2024, along with strategic acquisitions and partnerships to diversify revenue streams.

Evofem Biosciences has secured voting agreements from key investors to support its proposed merger with Aditxt, Inc., ensuring a favorable vote at the upcoming Special Meeting of Stockholders.

Evofem Biosciences has entered into support agreements with key institutional investors to back its merger with Aditxt, while also facing a notice of default on its debt obligations.

Evofem Biosciences completed a $2.28 million private placement of Series F-1 Preferred Stock with Aditxt, Inc. as part of a merger agreement.

Evofem Biosciences has amended its merger agreement with Aditxt, Inc., secured a $460,000 private placement, and is contesting a notice of default that could trigger a $106.8 million repurchase obligation.

Evofem Biosciences completed a private placement with Aditxt, Inc., issuing 260 shares of Series F-1 Preferred Stock for $260,000, as part of a merger agreement.

Evofem Biosciences and Aditxt have amended their merger agreement for a second time, pushing back key investment and consummation dates.